Medindia
Medindia LOGIN REGISTER
Advertisement

New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care

Saturday, June 5, 2010 General News
Advertisement
Integrated Analysis Shows Denosumab Superiority Over Zometa(R) In Delaying Or Preventing Skeletal Related Events In Broad Population With Advanced Cancer

CONTACT: Amgen, Thousand Oaks

Lisa Rooney: +1 (805) 559-0739 (media)

Arvind Sood: +1 (805) 447-1060 (investors)

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close